JP2021513357A5 - - Google Patents

Info

Publication number
JP2021513357A5
JP2021513357A5 JP2020543802A JP2020543802A JP2021513357A5 JP 2021513357 A5 JP2021513357 A5 JP 2021513357A5 JP 2020543802 A JP2020543802 A JP 2020543802A JP 2020543802 A JP2020543802 A JP 2020543802A JP 2021513357 A5 JP2021513357 A5 JP 2021513357A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
antibody
constant domain
flt3l
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020543802A
Other languages
English (en)
Japanese (ja)
Other versions
JP7525397B2 (ja
JP2021513357A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017877 external-priority patent/WO2019160976A1/en
Publication of JP2021513357A publication Critical patent/JP2021513357A/ja
Publication of JP2021513357A5 publication Critical patent/JP2021513357A5/ja
Priority to JP2023118763A priority Critical patent/JP7756686B2/ja
Application granted granted Critical
Publication of JP7525397B2 publication Critical patent/JP7525397B2/ja
Priority to JP2024195419A priority patent/JP2025013590A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543802A 2018-02-14 2019-02-13 ネコMcDonough肉腫(FMS)様チロシンキナーゼ3受容体リガンド(FLT3L)に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用 Active JP7525397B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023118763A JP7756686B2 (ja) 2018-02-14 2023-07-21 ネコMcDonough肉腫(FMS)様チロシンキナーゼ3受容体リガンド(FLT3L)に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用
JP2024195419A JP2025013590A (ja) 2018-02-14 2024-11-07 ネコMcDonough肉腫(FMS)様チロシンキナーゼ3受容体リガンド(FLT3L)に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630571P 2018-02-14 2018-02-14
US62/630,571 2018-02-14
PCT/US2019/017877 WO2019160976A1 (en) 2018-02-14 2019-02-13 Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023118763A Division JP7756686B2 (ja) 2018-02-14 2023-07-21 ネコMcDonough肉腫(FMS)様チロシンキナーゼ3受容体リガンド(FLT3L)に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用

Publications (3)

Publication Number Publication Date
JP2021513357A JP2021513357A (ja) 2021-05-27
JP2021513357A5 true JP2021513357A5 (https=) 2022-02-22
JP7525397B2 JP7525397B2 (ja) 2024-07-30

Family

ID=67619040

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020543802A Active JP7525397B2 (ja) 2018-02-14 2019-02-13 ネコMcDonough肉腫(FMS)様チロシンキナーゼ3受容体リガンド(FLT3L)に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用
JP2023118763A Active JP7756686B2 (ja) 2018-02-14 2023-07-21 ネコMcDonough肉腫(FMS)様チロシンキナーゼ3受容体リガンド(FLT3L)に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用
JP2024195419A Pending JP2025013590A (ja) 2018-02-14 2024-11-07 ネコMcDonough肉腫(FMS)様チロシンキナーゼ3受容体リガンド(FLT3L)に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023118763A Active JP7756686B2 (ja) 2018-02-14 2023-07-21 ネコMcDonough肉腫(FMS)様チロシンキナーゼ3受容体リガンド(FLT3L)に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用
JP2024195419A Pending JP2025013590A (ja) 2018-02-14 2024-11-07 ネコMcDonough肉腫(FMS)様チロシンキナーゼ3受容体リガンド(FLT3L)に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用

Country Status (13)

Country Link
US (3) US11512127B2 (https=)
EP (1) EP3752195A4 (https=)
JP (3) JP7525397B2 (https=)
KR (2) KR20250139415A (https=)
CN (2) CN111989117B (https=)
AU (2) AU2019222705B2 (https=)
BR (1) BR112020016400A2 (https=)
CA (1) CA3091184A1 (https=)
CL (1) CL2020002088A1 (https=)
IL (1) IL276598A (https=)
MX (2) MX2020008479A (https=)
SG (1) SG11202007702UA (https=)
WO (1) WO2019160976A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250139415A (ko) 2018-02-14 2025-09-23 호라이즌 테라퓨틱스 아일랜드 디에이씨 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3306063B2 (ja) 1990-08-24 2002-07-24 イグジス, インコーポレイテッド ランダムコドンを有するオリゴヌクレオチドを合成する方法
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
JP3298879B2 (ja) 1990-12-20 2002-07-08 イグジス,インコーポレイテッド 結合タンパク質の最適化
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6132994A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US7537932B1 (en) 1993-05-19 2009-05-26 Schering Corporation Antibodies that bind purified mammalian FLT3 ligands
US7045128B2 (en) * 1993-05-24 2006-05-16 Immunex Corporation Antibodies against flt3-ligand
US6630143B1 (en) * 1993-05-24 2003-10-07 Immunex Corporation Antibodies against flt3 ligand
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO1999006834A2 (en) 1997-08-04 1999-02-11 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
US6602994B1 (en) 1999-02-10 2003-08-05 Hercules Incorporated Derivatized microfibrillar polysaccharide
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP2005500508A (ja) * 2000-06-28 2005-01-06 アメリカ合衆国 ガスセンサのための気体ガス採取装置及びその方法
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
EP1351707B9 (en) * 2001-01-09 2012-01-25 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
ZA200503075B (en) 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
CN103251953A (zh) 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
US20060142430A1 (en) 2004-12-29 2006-06-29 Harrington John C Retention and drainage in the manufacture of paper
KR20160070165A (ko) * 2008-02-08 2016-06-17 메디뮨 엘엘씨 Fc 리간드 친화성이 감소된 항-IFNAR1 항체
EP2491177B1 (de) 2009-10-20 2020-02-19 Solenis Technologies Cayman, L.P. Verfahren zur herstellung von papier, pappe und karton mit hoher trockenfestigkeit
US20130156764A1 (en) * 2010-03-12 2013-06-20 The Johns Hopkins University Neutralization of flt3 ligand as a leukemia therapy
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
CN107073070A (zh) * 2014-08-15 2017-08-18 格纳西尼有限公司 治疗宫颈癌的方法
KR20250139415A (ko) 2018-02-14 2025-09-23 호라이즌 테라퓨틱스 아일랜드 디에이씨 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도

Similar Documents

Publication Publication Date Title
CN112135626A (zh) 抗tigit抗体及其用途
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2016505556A5 (https=)
JP2019516392A5 (https=)
CN110536903A (zh) 抗ox40抗体及其用途
HRP20131215T1 (hr) Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
JP2020514277A5 (https=)
JP2017149720A5 (https=)
RU2020130795A (ru) Нейтрализующие антитела к env вич-1 и их применение
HRP20200583T1 (hr) Protutijela koja neutraliziraju gp120 i njihova upotreba
RU2010149746A (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
RU2018135550A (ru) Связывающие ilt7 молекулы и способы их применения
JP2022533538A5 (https=)
RU2014153440A (ru) Антитела против cd26 и их применение
JP2021515541A5 (https=)
JP2024540148A5 (https=)
CN113563473A (zh) 四价双特异性抗体、其制备方法和用途
RU2019135404A (ru) Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний
JP2024516098A5 (https=)
JP2023510982A5 (https=)
JP2020513759A5 (https=)
JP2021512652A5 (https=)
RU2019103991A (ru) Анти-il-22r-антитела